Part 1 of this series looked at the regulatory pathways that are available to sponsors conducting clinical trials in Australia, focusing on ethics approval, site authorisation and TGA notification or approval. Part 2 examined the stakeholders sponsors encounter at each stage, from the ATO and FIRB during structuring through to HRECs, research governance officers and Medicines Australia.
In Part 3, we turn to the contracts that connect those stakeholders in Australia. Once ethics and governance approval are under way, the clinical trial agreement is where risk is allocated. In this Part, we consider the key themes for clinical trials contracting, assess how the Medicines Australia standard form addresses those requirements, and flag practical issues and recommendations for sponsors to consider.
The Medicines Australia standard form Clinical Trial Research Agreements (the Standard Form CTRAs) have become the de facto industry standard in Australia. Sponsors who depart materially from the Standard Form CTRAs typically face extended negotiation timelines. In our experience, few counterparties are prepared to accept non-standard terms.
Parties and the related agreements
The Standard Form CTRA governs the relationship between the Sponsor (or Local Sponsor) and the Institution at each Study Site. It also regulates the Principal Investigator’s role, imposing obligations on the Institution to ensure the Principal Investigator complies with the Protocol, obtains ethics approval, reports adverse events and maintains appropriate records.
Who’s who?
|
Sponsor |
The company that initiates, finances and takes regulatory responsibility for the trial. The Sponsor usually owns IP in Study Materials, provides an indemnity, and bears ultimate responsibility for participant safety and regulatory compliance. |
|
Institution |
The hospital, university or research institute where the trial is conducted. The Institution is the Sponsor’s contractual counterparty responsible for ensuring the Principal Investigator and site staff comply with the Protocol and applicable laws. |
|
Principal Investigator |
The lead clinician at the site — typically a senior doctor or academic researcher — who has day-to-day responsibility for conducting the trial. The Principal Investigator is not a party to the CTRA, but the Institution guarantees their performance. |
|
Local Sponsor |
Where a contract research organisation (CRO) acts as the local representative of an overseas company, the CRO becomes the Local Sponsor. The Local Sponsor steps into the Sponsor’s shoes for all purposes — including providing the indemnity to the Institution. |
|
Organisation |
The overseas pharmaceutical or biotech company that developed the trial and engaged the Local Sponsor. The Organisation is not a party to the CTRA, which means the Institution has no direct contractual recourse against it if something goes wrong. |
|
CRG |
A Collaborative or Cooperative Research Group — typically an academic consortium or disease-specific research network — that sponsors investigator-initiated trials. CRGs are usually non-commercial entities, and the CTRA reflects a more cooperative relationship than the commercial Sponsor templates. |
The Medicines Australia suite includes templates for three commercial structures: direct sponsorship by the commercial Sponsor, a CRO acting as Local Sponsor on behalf of an overseas Organisation, and collaborative or cooperative research group studies.
Where a CRO acts as Local Sponsor, it is the Local Sponsor (not the overseas Organisation) that provides the indemnity to the Institution. The Organisation is not a party to the agreement, and the Institution has no direct recourse against it. Beyond party structure, the Standard Form CTRA also imposes operational obligations — including monitoring visits and adverse event reporting — that require coordination across Sponsor, CRO and site.
Issues to consider
- Have you mapped how your CRO arrangements interact with the Standard Form CTRA?
- Does the Principal Investigator need a separate agreement — for example, to address IP assignments or post-employment confidentiality?
- Who will handle monitoring, and under what arrangements?
- Are your adverse event reporting workflows documented across Sponsor, CRO and site?
Which Standard Form CTRA do I use?
|
Contracting party
|
Phase 1–3 trials (unregistered products)
|
Phase 4 trials (registered products)
|
|
The commercial sponsor The Sponsor contracts with the Institution directly. |
Clinical Trial Research Agreement, Medicines Australia Standard Form This agreement governs most commercially sponsored trials. |
Clinical Trial Research Agreement, Phase 4 Clinical Trial (Medicines) This version applies where the product is registered and is supplied within the conditions of its registration. |
|
A CRO acting as Local Sponsor The CRO contracts with the Institution as Local Sponsor. The overseas Organisation stands outside the agreement. |
Clinical Trial Research Agreement, Contract Research Organisation acting as the Local Sponsor |
Clinical Trial Research Agreement, Phase 4 Clinical Trial (Medicines), Contract Research Organisation acting as the Local Sponsor |
|
A collaborative or cooperative research group A non-commercial entity sponsors the trial. The research group takes the role of Sponsor, and each participating site is the Institution. |
Clinical Trial Research Agreement, Collaborative or Cooperative Research Group Studies A single agreement covers every phase. Where the trial is supported by grant funding from the National Health and Medical Research Council, the Medical Research Future Fund or Cancer Australia, the approved clauses for the relevant funder are incorporated. |
|
Indemnity and compensation
Participants in clinical trials are often exposed to investigational products with incomplete safety profiles, to procedures they would not otherwise undergo, and to risks that cannot be fully quantified at the outset. When something goes wrong, there are two questions: what protects the Institution, and how are participants compensated.
The Standard Form CTRA contemplates execution of a separate Form of Indemnity, protecting the Institution against claims made by participants. The Compensation Guidelines require the Sponsor to compensate injured participants without proof of fault if the claim satisfies five conditions.
Applying the Compensation Guidelines
To qualify for compensation, a claim must satisfy all five conditions, most sensibly evaluated in sequence. If any condition is not met, the claim falls outside the scheme and the participant may revert to their other rights to compensation.
Key questions when applying the Compensation Guidelines
|
Scope |
Does the trial fall within the Guidelines? The Guidelines apply to sponsor-initiated trials of unregistered products, or registered products used outside their approved indications. |
|
Causation |
Is the injury attributable to the trial? The injury must result from the product or a procedure the participant would not otherwise have undergone. |
|
Severity |
Is the injury serious, enduring and disabling? Temporary discomfort or readily curable complaints fall outside the scheme. |
|
Exclusions |
Does the claim avoid the express exclusions? Claims based on lack of efficacy, placebo allocation or injury from a registered comparator product are excluded. |
|
Intervening causes |
Did some other fault contribute to the injury? Compensation may be reduced if the injury arose from protocol departure, third-party fault or participant negligence. |
The Standard Form CTRA contains no cap on general contractual liability. If desired, a cap must be negotiated and introduced by a special condition. Insurance is addressed through a certificate mechanism, with the Sponsor undertaking to maintain appropriate cover and provide evidence on request.
Issues to consider
- Has the Form of Indemnity been executed — and if not, when will it be?
- Are there claims that might fall outside the Compensation Guidelines — for example, injuries involving placebo or comparator products?
- Are there protocol procedures that could complicate causation — for example, where injury may be attributable to standard care rather than the Investigational Product?
Intellectual property and publication rights
Clinical trials generate highly valuable intellectual property that is often the culmination of significant investment. The Standard Form CTRA provides that IP in Study Materials generated during the conduct of the trial vests in the Sponsor, and if the Institution contributes background IP, the Sponsor receives a broad licence to that IP for the purpose of commercialisation.
Publication rights sit at the centre of the tension between academic freedom and IP protection. The Standard Form CTRA gives investigators the right to publish, but subject to a pre-publication review process that allows the Sponsor to comment, request removal of confidential information, or delay publication to provide an opportunity to file patents. For example, in multi-centre studies, individual site results are withheld until pooled results are published or two years after Study Completion.
The Sponsor has 40 days to review a proposed publication. If patentable subject matter is generated, the Sponsor can request an additional 120 days to file an application for a patent — but only if it identifies the issue within the initial window. For Sponsors with complex IP strategies, that timeline can be tight.
Issues to consider
- If the Institution is contributing proprietary techniques or know-how, is the background IP licence broad enough for the intended commercialisation?
- If patentable subject matter may be produced, is there enough time to identify that intellectual property and file an application so as to avoid disclosure invalidating any patent that is granted on the application?
- Is there a process for reviewing publication drafts to identify Confidential Information that should be removed before the 40-day review period expires?
Data, samples and privacy
The Standard Form CTRA addresses information relating to Study Participants and samples that are taken from them, but leaves other matters for Sponsors to address in the consent form, Protocol, and special conditions.
The Standard Form CTRA requires each party to handle Personal Information in accordance with Relevant Privacy Laws and to report data breaches. However, there is little detail on operational compliance given the sensitive nature of health information. For public sector institutions like hospitals, the applicable privacy laws can vary between State and Territories.
The Standard Form CTRA vests IP in Study Materials — which includes Biological Samples — in the Sponsor. However IP ownership does not necessarily travel with ownership of physical samples, and questions of tissue ownership, use beyond the Protocol, and consent withdrawal may need to be addressed.
Issues to consider
- Should any of the parties consider a Privacy Impact Assessment?
- If Study data will be transferred overseas, have cross-border disclosure requirements been addressed in consents?
- Do Foreign Investment Review Board conditions apply to any health data that is generated?
- Is ownership of physical samples addressed? What happens to them if a participant withdraws consent?
Payment structure
Clinical trials require funding for site costs, staff time, facilities, and overheads. The payment structure determines how those costs are recovered, when payments fall due, and what happens if the trial does not run to completion.
The Standard Form CTRA provides a framework but leaves the commercial detail to the parties. However, the substance of the payment arrangement — amounts, timing, and triggers — must be drafted in Schedule 2. The template provides seven headings but no default content.
An incomplete or vague Schedule 2 is a common source of disputes.
Issues to consider – for Payment Terms
|
Trial Initiation |
The initiation payment covers site set-up costs before recruitment begins. If the trigger is unclear — ethics approval, first patient enrolled, or site activation — the Institution may incur costs before the payment is due, or the Sponsor may pay before value is delivered. Consider specifying the trigger event and whether the payment is refundable if the trial does not proceed. |
|
Patient Enrolment |
Patient payments are usually the largest component of trial funding. If the agreement does not specify when the fee is earned — screening, enrolment, or completion — disputes can arise over screen failures and early withdrawals. Consider whether payments are per-patient or milestone-based, and at what point each fee is earned. |
|
Staged Payments |
Staged payments align cash flow with trial progress. If the phasing is unclear, the Institution may face funding gaps between milestones, or the Sponsor may overpay relative to work completed. Consider how payments are phased — by visit, by quarter, or by recruitment milestone — and what documentation triggers each payment. |
|
Trial Closeout and timing of final payment |
Final payment is typically the largest single instalment. If the conditions for release are unclear — database lock, query resolution, return of product — the Sponsor may withhold payment indefinitely while the Institution has already incurred the costs. Consider specifying the conditions and a reasonable timeframe for final payment. |
|
Early Termination Fees |
Trials end early for many reasons — a safety signal, futility, a commercial decision, or a global event that disrupts recruitment. Early termination leaves the Institution with sunk costs and participants in the middle of treatment. The Standard Form CTRA permits termination on 30 days' notice but leaves funding for wind-down to be agreed. Consider specifying fees for work in progress, committed expenditure, and participant transition. |
|
Fees for Protocol Variation |
Protocol amendments are common as trials progress. If there is no pricing mechanism, each amendment becomes a negotiation — delaying implementation and straining the relationship. Consider whether amendments are priced at a fixed fee, time and materials, or a formula, and what happens if the parties cannot agree. |
|
Matters to be reimbursed |
Sites incur out-of-pocket costs that fall outside the per-patient fee — travel, couriers, archiving, ethics submissions. If reimbursement terms are unclear, the Institution absorbs costs it expected to recover, or disputes arise over what requires pre-approval. Consider specifying which costs are to be reimbursed, any cap or threshold, and the approval process. |
Artificial intelligence and clinical trials
Clinical trials increasingly involve artificial intelligence — for patient screening, adverse event detection, imaging analysis, and data management. Where AI is used, the Standard Form CTRA’s existing framework may not address who owns the outputs, and whether Study data can be used to train the model.
Many of the ethical and regulatory issues are considered as part of the HREC approval process. However, the Standard Form CTRA was drafted before generative artificial intelligence had applications for clinical trials.
Issues to consider
- If Study data will be used as inputs for AI training or generative AI, have participants specifically consented and do privacy authorisations support that use?
- Do any AI-generated outputs fall within the definition of Study Materials— or does IP ownership need to be clarified by special condition, particularly where a third-party AI vendor retains rights in the underlying model?
Conclusion
Australia remains an attractive destination for clinical trials. The regulatory pathway is well established, the research infrastructure is high quality, and the Standard Form CTRAs provide a solid contractual foundation. For Sponsors willing to engage with the detail — and to use Schedule 7 to address matters the templates leave open — the framework is flexible enough to accommodate complex, multi-site, and increasingly technology-driven trials.
The common thread across this series is the value of early planning. Sponsors who engage with the commercial and legal detail before site agreements are signed — addressing payment triggers, IP strategy, data flows, and liability allocation upfront — are best placed to take advantage of opportunities in Australia.
